Tags |
|
|
Links |
|
|
Summary - How Do I Trust Again?
I came across a question recently. In brief the poster wanted
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
to know how she could trust any man again. Two men one after
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
other ditched her and the second one was very close. She want
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ed to know if she should try any new relationship at all or f
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
rget it.
This is a tricky question and needs to be addressed
This is a tricky question and needs to be addressed
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
from many angles. Let us first think about the posters person
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ality. Is she of a very trusting nature? Does she continue tr
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
sting even after getting clear signals? Is wishful thinking m
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
rring her logical judgment? Why was she ditched twice and cou
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ld not anticipate it? This surely may have been a case of ext
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
eme bad luck but what if she herself behaves in such a manner
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
that her partners run away after sometime? The personality of
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
the poster is very important to consider.
In the second hal
In the second hal
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
we have to look at the personality of people who breach the
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
rust. They are people of low morals and may look for a quick
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
relationship only for physical pleasure. As soon as they get
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
omebody better they leave the first. These people have no lon
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
-term commitment and that can be gauged from their behavior a
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
nd talk. Before getting deeply involved with such people keep
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
eyes and ears open. You will get ample hints about the future
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.summary.org.ua/article/200198/summary-How-Do-I-Trust-Again.html">How Do I Trust Again?</a>
BB link (for phorums):
[url=http://www.summary.org.ua/article/200198/summary-How-Do-I-Trust-Again.html]How Do I Trust Again?[/url]
Related Articles:
The Key Factor in Good Advertising
Bookmark it:
|